GFP expressing influenza A virus

Sarah De Baets, Judith Verhelst, Silvie Van den Hoecke, Anouk Smet, Michael Schotsaert, Emma R. Job, Kenny Roose, Bert Schepens, Walter Fiers, and Xavier Saelens. (2015) A GFP Expressing Influenza A Virus to Report In Vivo Tropism and Protection by a Matrix Protein 2 Ectodomain-Specific Monoclonal Antibody. PLoS One. 2015; 10(3): e0121491.

Broad bispecific antibody against influenza virus

Wagner K, Kwakkenbos MJ, Claassen YB, Maijoor K, Böhne M, van der Sluijs KF, Witte MD, van Zoelen DJ, Cornelissen LA, Beaumont T, Bakker AQ, Ploegh HL, Spits H. (2014) Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity. Proc Natl Acad Sci U S A. 111(47):16820-5

Promising results in the Journal of Infectious Diseases!

J.H.C.M. Kreijtz, L.C.M. Wiersma, H.L.M. Gruyter De, S.E. Vogelzang-van Trierum, G. van Amerongen, K.J. Stittelaar, R.A.M. Fouchier, A.D.M.E. Osterhaus, G. Sutter and G.F. Rimmelzwaan (2014) A single immunization with a modified Vaccinia Virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model. The Journal of Infectious Diseases 10.1093/infdis/jiu528

Review in Viruses

Arwen F. Altenburg, Joost H. C. M. Kreijtz, Rory D. de Vries, Fei Song, Robert Fux, Guus F. Rimmelzwaan, Gerd Sutter and Asisa Volz (2014) Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases. Viruses 2014, 6, 2735-2761; doi:10.3390/v6072735

Publication in Journal of Virology

Asisa Volz, Martin Langenmayer, Sylvia Jany, Ulrich Kalinke and Gerd Sutter (2014) Rapid expansion of CD8+ T cells in wildtype and type I interferon receptor deficient mice correlates with protection after low-dose emergency immunization with Modified Vaccinia virus Ankara. Journal of Virology Published ahead of print 9 July 2014, doi: 10.1128/JVI.00945-14


FLUNIVAC aims at developing a candidate influenza vaccine based on recombinant Modified Vaccinia virus Ankara viruses (rMVA) encoding both B-cell and T- cell response-inducing proteins, ready to commence Phase I clinical trials. We focus on influenza A virus since it is the most pathogenic variant to humans and causes all manifestations of human influenza: zoonotic, […]